1. Home
  2. CCO vs RARE Comparison

CCO vs RARE Comparison

Compare CCO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clear Channel Outdoor Holdings Inc.

CCO

Clear Channel Outdoor Holdings Inc.

HOLD

Current Price

$2.46

Market Cap

1.2B

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

SELL

Current Price

$14.82

Market Cap

1.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CCO
RARE
Founded
1995
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
2005
2013

Fundamental Metrics

Financial Performance
Metric
CCO
RARE
Price
$2.46
$14.82
Analyst Decision
Hold
Buy
Analyst Count
3
20
Target Price
$2.43
★ $26.79
AVG Volume (30 Days)
4.9M
★ 5.1M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
★ 22.95%
N/A
EPS Growth
★ 110.81
7.31
EPS
★ N/A
N/A
Revenue
★ $1,604,140,000.00
$673,000,000.00
Revenue This Year
$6.61
$13.03
Revenue Next Year
$3.02
$30.66
P/E Ratio
★ N/A
N/A
Revenue Growth
6.57
★ 20.13
52 Week Low
$1.37
$12.73
52 Week High
$2.44
$39.89

Technical Indicators

Market Signals
Indicator
CCO
RARE
Relative Strength Index (RSI) 65.68 39.30
Support Level $2.34 $13.95
Resistance Level N/A $15.81
Average True Range (ATR) 0.04 0.69
MACD 0.01 0.41
Stochastic Oscillator 94.20 47.58

Price Performance

Historical Comparison
CCO
RARE

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: